Sedation Policy in Emergency Department
Core Policy Framework
A comprehensive ED procedural sedation policy must mandate specific drug regimens, continuous physiologic monitoring, immediate airway rescue capability, and structured documentation for both adult and pediatric populations, with provider competence being the paramount safety factor. 1
Drug Regimens
Adult Patients - First-Line Options
Fentanyl-midazolam combination is the primary recommended regimen with Level B evidence from the American College of Emergency Physicians 2:
- Initial dosing: Fentanyl 50-100 µg IV first (due to greater respiratory depression risk), followed by midazolam 1-2 mg IV 2
- Supplemental dosing: Fentanyl 25 µg every 2-5 minutes; allow 2-5 minutes between doses to assess maximum effect 2
- Onset/duration: Fentanyl onset 1-2 minutes, duration 30-60 minutes 2
- Critical caveat: This combination causes hypoxemia in 92% and apnea in 50% of patients—dose reduction of each component is mandatory 2
Alternative Adult Regimens
Propofol (Level B recommendation from American Society of Anesthesiologists) 2:
- Dosing: 1 mg/kg IV initial, 0.5 mg/kg supplemental doses 2
- Advantages: Significantly shorter recovery time (14.9 vs 76.4 minutes for midazolam), 92% procedure success rate 2
- Limitation: Requires deeper sedation levels; avoid in hemodynamically unstable patients 2
Etomidate 2:
- Dosing: 0.15-0.2 mg/kg IV 2
- Indication: Preferred over propofol in hemodynamically unstable patients due to superior cardiovascular stability 2
- Duration: Shorter than midazolam (median 10 vs 23 minutes) 2
Ketamine 2:
- Dosing: 1.5-2 mg/kg IV (can give IM if IV access difficult) 1
- Unique advantage: Provides analgesia and sedation without depressing airway reflexes 2
- Onset/duration: 1 minute IV onset, 10-15 minute duration 2
- Side effect: 7% recovery agitation rate (adding midazolam doesn't reduce this) 2
- Special indication: Particularly suitable for asthma patients as it preserves protective airway reflexes 1
Pediatric Patients
Non-pharmacological approaches should be attempted first in children capable of engaging with distraction techniques 3:
- Hydroxyzine: FDA-approved anxiolytic for pediatric procedural anxiety, available in tablet and syrup formulations 3
- Nitrous oxide: Provides effective analgesia and anxiolysis with minimal side effects, though 20-30% failure rate and less effective in very young children 3
- Contraindications for nitrous oxide: Pneumothorax, bowel obstruction, cardiovascular compromise 3
High-Risk Population Modifications
Reduce initial sedative/analgesic doses by 50% in patients >60 years or with comorbidities, then titrate slowly with smaller increments 2:
- Elderly/obese/hepatic-renal impairment: Fentanyl clearance is reduced—mandatory dose reduction 2
- Renal insufficiency: Prefer fentanyl over meperidine (meperidine's half-life significantly prolonged, increasing neurotoxicity risk from normeperidine accumulation) 2
Monitoring Requirements
Continuous Physiologic Monitoring
Capnometry is recommended to provide early identification of hypoventilation, especially critical when using benzodiazepine-opioid combinations 2, 3:
- Pulse oximetry: Mandatory in high-risk patients (high medication doses, multiple medications, significant comorbidities) 2
- Timing principle: Allow sufficient time between doses to assess maximum effect before administering additional medication 2
Post-Procedure Monitoring
Minimum 2-hour observation after naloxone administration to ensure resedation does not occur 2:
- Recovery to presedation level of consciousness required before discharge 4
- Properly equipped and staffed recovery area mandatory 4
Airway Management and Rescue Capability
Equipment and Personnel Requirements
Immediate availability of resuscitative drugs, age-appropriate airway equipment, and personnel trained in airway management is mandatory 1:
- Reversal agents: Naloxone and flumazenil must be immediately available if using opioids or benzodiazepines 2, 1
- Personnel: Sufficient numbers to both carry out the procedure AND monitor the patient 4
- Critical principle: Complications arise from inability to manage adverse events, not from the agent itself 1
Provider Competence
Provider familiarity with the chosen agent is paramount for safe sedation practice—never use an unfamiliar sedation agent simply because it seems theoretically ideal 1:
- Selection of sedation agents depends on experience, training, and preference of the individual practitioner 1
- Sedation providers must plan the regimen based on identified needs with understanding that provider familiarity is essential 1
Documentation Requirements
Mandatory Documentation Elements
A preprinted form significantly improves documentation quality—when used, 80.4% of medical records had good documentation with none having poor documentation, compared to only 1.4% good documentation when not used 5:
The policy should mandate documentation of 22 critical items distilled from published guidelines 5:
- Pre-sedation: Patient assessment, fasting status, airway examination, comorbidities, informed consent 4, 6
- Intra-procedure: Medications administered (drug, dose, route, time), vital signs at regular intervals, level of sedation achieved, adverse events 5
- Post-procedure: Recovery time, discharge vital signs, discharge instructions, follow-up plans 4, 5
Important clarification: Current evidence shows non-compliance with elective fasting guidelines does not increase aspiration risk, and urgent procedures should not be delayed due to fasting status 1
Special Clinical Scenarios
Drug Administration Authority
Drug administration for anxiolysis should only be performed by authorized, qualified personnel according to hospital and national regulations 3:
- Sedation without the safety net of medical/dental supervision is prohibited 4
- Systematic approach required including presedation evaluation for conditions placing child at increased risk 4
Focused Airway Examination
Pre-sedation airway assessment must identify large (kissing) tonsils or anatomic abnormalities that might increase airway obstruction potential 4: